HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery // AI-driven insights complement human-curated QIAGEN Biomedical KB-HD and help identify novel relationships between diseases, biological pathways and molecular interactions that may be missed by traditional methods // Workflow cuts down on hypothesis testing time and speeds up the identification of promising therapeutic avenues with clear, structured data QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery // AI-driven insights complement human-curated QIAGEN Biomedical KB-HD and help identify novel relationships between diseases, biological pathways and molecular interactions that may be missed by traditional methods // Workflow cuts down on hypothesis testing time and speeds up the identification of promising therapeutic avenues with clear, structured data
Read more:
QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery
ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 7, 2024, at 4:30 pm ET.
Go here to see the original:
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced that it received a delinquency notification letter (“Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) on February 21, 2024 due to the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 (the “Form 10-Q”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”).
See original here:
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
Ad hoc announcement pursuant to Art. 53 LR
Go here to read the rest:
Idorsia and Viatris enter into a significant global research and development collaboration
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
Read this article:
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
Press Release
Read the rest here:
Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO
PARIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral gene therapies with minimally-invasive delivery technology, launches today with seed finance from Pureos Bioventures and ND Capital. It is poised to clinically validate its highly innovative delivery platform by advancing two first-in-class late-stage preclinical drugs for wet and dry age-related macular diseases (AMD), including geographic atrophy (GA), major diseases of the elderly leading to blindness.
Blastocyst illustration. A blastocyst is a hollow ball of cells with a fluid centre formed after several divisions of a fertilised cell (zygote). The inner cell mass (purple) contains the cells that will form the embryo proper, the embryonic stem cells (ESCs). Kateryna Kon/Science Photo Library/Getty Images hide caption
Blastocyst illustration. A blastocyst is a hollow ball of cells with a fluid centre formed after several divisions of a fertilised cell (zygote). The inner cell mass (purple) contains the cells that will form the embryo proper, the embryonic stem cells (ESCs).
Since the first successful in vitro fertilization pregnancy and live birth in 1978, nearly half a million babies have been born using IVF in the United States. Since the first successful in vitro fertilization pregnancy and live birth in 1978, nearly half a million babies have been born using IVF in the United States. Reproductive endocrinologist Amanda Adeleye explains the science behind IVF, the barriers to accessing it and her concerns about fertility treatment in the post-Roe landscape.
For more on IVF success rates, check out the Society for Assisted Reproductive Technology's database.
Questions or ideas for a future episode of Short Wave? Email us at shortwave@npr.org we'd love to hear from you!
Listen to Short Wave on Spotify, Apple Podcasts and Google Podcasts.
Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.
This episode was produced by Berly McCoy and Rebecca Ramirez. It was edited by Brit Hanson and Rebecca Ramirez. Brit checked the facts. The audio engineer was Josh Newell.
See the original post:
In light of the Alabama court ruling, a look at the science of IVF : Short Wave - NPR